The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Jounce Therapeutics, Inc(NASDAQ:JNCE) 
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on...
Website: http://www.jouncetx.com
Founded: 2012
Full Time Employees: 129
Sector: Healthcare
Industry: Biotechnology
Jounce Therapeutics Op Cashflow Per Share ttm
Jounce Therapeutics Free Cashflow Per Share ttm
Jounce Therapeutics Cash Per Share ttm
Jounce Therapeutics P/S ratio ttm
Jounce Therapeutics (GAAP) P/E ratio ttm
Jounce Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.